Everything below concerns AOD9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
=== Cancer === Preliminary studies suggest that FFAR2 may be involved in some types of cancer. 1) One study found that FFAR2 levels were elevated in human stomach and colorectal cancers although another study reported that FFAR2 levels were markedly deceased in human colorectal cancer. These results suggest that FFAR2 may promote the development and/or progression of human stomach cancer but its impact on human colorectal cancer requires further study. 2) In a dextran sulfate sodium-induced model of inflammation-associated colon cancer, FFAR2 knockdown mice developed larger and more tumors than control mice. This study suggests that FFAR2 inhibits the development and/or progression of inflammation-associated colon carcinoma in mice; its role in human inflammation-associated colorectal cancer (e.g., colorectal cancer developing in ulcerative colitis) has not been clarified. 3) Compared to their normal lung tissues, the lung cancer tissues of 42 patients had lower levels of FFAR2 but not FFAR1, FFAR3, or FFAR4. 4) Butyric acid inhibited the proliferation of and triggered apoptosis in cultured human A549 lung cancer cells; further studies in A549 as well as H1299 human lung cancer cells found that propionic acid inhibited their stimulated migration, invasiveness, and colony growth in cell culture assays but did not do so in FFAR2 gene knockout A549 or H1299 cells. These results suggest that FFAR2 may inhibit the development and/or progression of human lung cancer.
== Other animals == The rectus abdominis is similar in most vertebrates. The most obvious difference between animal and human abdominal musculature is that in animals, there are a different number of tendinous intersections.
This resulted in the publication of the report, The Double Bind: The Price of Being a Minority Woman in Science (1976) which made recommendations for recruiting and retaining minority women scientists. Daly was a member of the board of governors of the New York Academy of Sciences for two years. She was a fellow of the American Association for the Advancement of Science and of the American Cancer Society. Daly was designated as a career scientist by the Health Research Council of the City of New York. Daly retired in 1986 from the Albert Einstein College of Medicine, and in 1988 established a scholarship for African American chemistry and physics majors at Queens College in memory of her father. In 1999, she was recognized by the National Technical Association as one of the top 50 women in Science, Engineering and Technology.
The Italian endorsement of the Declaration had included the condition "... on the understanding that there is no prejudice against the legal and political status of the already existing religious communities ..." The boundaries of Palestine were left unspecified, to "be determined by the Principal Allied Powers." Three months later, in July 1920, the French defeat of Faisal's Arab Kingdom of Syria precipitated the British need to know "what is the 'Syria' for which the French received a mandate at San Remo?" and "does it include Transjordania?" – it subsequently decided to pursue a policy of associating Transjordan with the mandated area of Palestine without adding it to the area of the Jewish National Home. In 1922, Congress officially endorsed America's support for the Balfour Declaration through the passage of the Lodge–Fish Resolution, notwithstanding opposition from the State Department. Professor Lawrence Davidson, of West Chester University, whose research focuses on American relations with the Middle East, argues that President Wilson and Congress ignored democratic values in favour of "biblical romanticism" when they endorsed the declaration. He points to an organized pro-Zionist lobby in the United States, which was active at a time when the country's small Arab American community had little political power.
Early European alchemists gave sulfur an alchemical symbol of a triangle atop a cross (🜍). Another type of sulfur mentioned in alchemy, black sulfur (sulfur nigrum), also had its own symbol combining a two-barred cross atop a lemniscate (🜏). This symbol was later used by Anton LaVey as a satanist symbol, the "Leviathan cross", as he associated it with the brimstone of Hell. This has led to some confusion and misconceptions about its original alchemical meaning: in alchemical texts, black sulfur was not a synonym for "brimstone" or an alternative symbol for sulfur as one of the Three Primes, but was instead considered a distinct type of sulfur, listed separately. Black sulfur, also known as grey sulfur (sulfur griseum) or "horse brimstone" (sulfur caballinum), was a grey, impure form of sulfur, usually the dregs of sulfur purification, which was used for medicinal purposes despite often containing arsenic. Iron shavings or hammerscale were sometimes added to it in its manufacture. The "horse" in the name is thought to reference its veterinary use: low quality sulfur, only fit to treat horses. In the 19th century, it was sometimes also sold under the name "sulphur of ivy" (a corruption of sulfur vivum) and used on hops.
Sources: en.wikipedia.org
A number of protease inhibitors are being developed targeting 3CLpro and homologous 3Cpro, including CLpro-1, GC376, AG7404, lufotrelvir, nirmatrelvir, ratutrelvir, rupintrivir. The intravenous administered prodrug PF-07304814 (lufotrelvir) entered clinical trials in September 2020. After clinical trials, in December 2021, the oral medication nirmatrelvir (formerly PF-07321332) became commercially available under emergency use authorizations (EUA), as part of the nirmatrelvir/ritonavir combination therapy (brand name Paxlovid). In May 2023, the medication got full FDA approval for high-risk adults, while children 12–18 were still covered under the EUA. The 3C-like protease inhibitor ensitrelvir received authorization to treat COVID-19 in Japan in 2022. In 2022, an ultralarge virtual screening campaign of 235 million molecules was able to identify a novel broad-spectrum inhibitor targeting the main protease of several coronaviruses. It is unusually not a peptidomimetic.
Historians agree that films have largely shaped historical memories, but they debate issues of accuracy, plausibility, moralism, sensationalism, how facts are stretched in search of broader truths, and suitability for the classroom. Ira Berlin argues that critics complain if the treatment emphasizes historical brutality, or if it glosses over the harshness to highlight the emotional impact of slavery.
== Ease of doing business == World Bank's Doing Business 2017; Equal Opportunity for All: Thailand ranked 46th (1-easiest; 190=difficult) of 190 nations in the "Ease of Doing Business" rankings. Other ASEAN states ranked: Singapore, 2; Malaysia, 23; Brunei, 72; Vietnam, 82; Indonesia, 91; Philippines, 99; Cambodia, 131; Laos, 139; Myanmar, 170. World Bank's Doing Business 2016: Measuring Regulatory Quality and Efficiency: Thailand ranked 49th overall of 189 nations (1=best, 189=worst) in ease of doing business, a drop of three places in the rankings since the 2014 survey prior to the May coup. Among ASEAN nations, Thailand ranked third behind Singapore and Malaysia. In detailed rankings, Thailand ranked 97th worldwide in getting credit, 96th in ease of starting a business, 70th in paying taxes, 39th in dealing with construction permits, 57th in registering property and enforcing contracts, 56th in trading across borders, 36th for protecting minority investors, and 49th in resolving insolvency.
== Hyperfibrinogenemia == Levels of functionally normal fibrinogen increase in pregnancy to an average of 4.5 gram/liter (g/L) compared to an average of 3 g/L in non-pregnant people. They may also increase in various forms of cancer, particularly gastric, lung, prostate, and ovarian cancers. In these cases, the hyperfibrinogenemia may contribute to the development of pathological thrombosis. A particular pattern of migratory superficial vein thrombosis, termed trousseau's syndrome, occurs in, and may precede all other signs and symptoms of, these cancers. Hyperfibrinogenemia has also been linked as a cause of persistent pulmonary hypertension of the newborn and post-operative thrombosis. High fibrinogen levels had been proposed as a predictor of hemorrhagic complications during catheter-directed thrombolysis for acute or subacute peripheral native artery and arterial bypass occlusions. However, a systematic review of the available literature until January 2016 found that the predictive value of plasma fibrinogen level for predicting hemorrhagic complications after catheter-directed thrombolysis is unproven.
Through this catabolic process, GSNOR regulates the cellular concentrations of GSNO and plays a central role in regulating the levels of endogenous S-nitrosothiols and controlling protein S-nitrosylation-based signaling. As an example of S-nitrosylation-based signaling, Barglow et al. showed that GSNO selectively S-nitrosylates reduced thioredoxin at cysteine 62. Nitrosylated thioredoxin, via directed protein-protein interaction, trans-nitrosylates the active site cysteine of caspase-3 thus inactivating caspase-3 and preventing induction of apoptosis. As might be expected of an enzyme involved in regulating NO levels and signaling, pleiotropic effects are observed in GSNOR knockout models. Deleting the GSNOR gene from both yeast and mice increased the cellular levels of GSNO and nitrosylated proteins, and the yeast cells showed increased susceptibility to nitrosative stress. Null mice show increased levels of S-nitrosated proteins, increased beta adrenergic receptor numbers in lung and heart, diminished tachyphylaxis to β2-adrenergic receptor agonists, hyporesponsiveness to methacholine and allergen challenge and reduced infarct size after occlusion of the coronary artery. In addition, null mice show increased tissue damage and mortality following challenge with bacteria or endotoxin and are hypotensive under anesthesia yet normotensive in the conscious state.
Sources: en.wikipedia.org
Such methods have been applied for discovering protein interactions on human interactome, specifically the interactome of Membrane proteins and the interactome of Schizophrenia-associated proteins. As of 2020, a model using residue cluster classes (RCCs), constructed from the 3DID and Negatome databases, resulted in 96-99% correctly classified instances of protein–protein interactions. RCCs are a computational vector space that mimics protein fold space and includes all simultaneously contacted residue sets, which can be used to analyze protein structure-function relation and evolution.
== Integrated Top-Down Proteomics (iTDP) == Further developed, refined, and optimized since the original report of a routine multi-dimensional separation of protein species (most often using isoelectric focusing and then SDS-PAGE), and subsequently coupled with western blotting and MS, this approach was the first to identify the range of protein species/proteoforms in a variety of samples. Currently, the iTDP analytical approach offers the highest proteoform resolution and a routine approach to full proteome analysis (e.g., across the full breadth of species in native proteomes). In the case of 2D-PAGE, spots and/or regions of interest can be excised from the gel, proteolytically digested using well-established methods, and the resulting peptides then assessed using LC/MS/MS to identify canonical amino acid sequences and their inherent PTM (i.e. an 'integration' with BUP). Integration of this sequence information with the isoelectric point (pI) and molecular weight (MW) information from 2DE thus enables definitive identification of proteoforms based on several key defining physico-chemical characteristics. In addition to highly sensitive and quantitative total proteoform detection using fluorescent stains[20]. and notably Coomassie Brilliant Blue as a near-IR dye, gel staining protocols also enable the identification of broad proteoform groups containing the same PTM (e.g. phospho- and glyco-proteoforms). Thus, iTDP utilizes integration of the best available approaches to enable truly comprehensive, deep proteome analyses at the critically necessary level of proteoforms.
== Structure == Sucrose is a disaccharide formed from condensation of glucose and fructose to produce α-D-glucopyranosyl-(1→2)-β-D-fructofuranoside. Sucrose has 8 hydroxyl groups which can be reacted with fatty acid esters to produce sucrose esters. Among the 8 hydroxyl groups on sucrose, three (C6, C1', and C6') are primary while the others (C2, C3, C4, C3', and C4') are secondary. (The numbers 1-6 indicate the position of the carbons on glucose while the numbers 1'-6' indicate the position of the carbons on fructose.) The three primary hydroxyl groups are more reactive due to lower steric hindrance, so they react with fatty acids first, resulting in a sucrose mono-, di-, or triester. Typical saturated fatty acids that are used to produce sucrose esters are lauric acid, myristic acid, palmitic acid, stearic acid and behenic acid, and typical unsaturated fatty acids are oleic acid and erucic acid.
== Mass spectrometry == Radical cations appear prominently in mass spectrometry. When a gas-phase molecule is subjected to electron ionization one electron is abstracted by an electron in the electron beam to create a radical cation M+.. This species represents the molecular ion or parent ion. A typical mass spectrum shows multiple signals because the molecular ion fragments into a complex mixture of ions and uncharged radical species. For example, the methanol radical cation fragments into a methenium cation CH+3 and a hydroxyl radical. In naphthalene the unfragmented radical cation is by far the most prominent peak in the mass spectrum. Secondary species are generated from proton gain (M+1) and proton loss (M-1).
==== Response and fallout ==== Although the experimental protocol had not been published, physicists in several countries attempted, and failed, to replicate the excess heat phenomenon. The first paper submitted to Nature reproducing excess heat, although it passed peer review, was rejected because most similar experiments were negative and there were no theories that could explain a positive result; this paper was later accepted for publication by the journal Fusion Technology. Nathan Lewis, professor of chemistry at the California Institute of Technology, led one of the most ambitious validation efforts, trying many variations on the experiment without success, while CERN physicist Douglas R. O. Morrison said that "essentially all" attempts in Western Europe had failed. Even those reporting success had difficulty reproducing Fleischmann and Pons' results. On 10 April 1989, a group at Texas A&M University published results of excess heat and later that day a group at the Georgia Institute of Technology announced neutron production—the strongest replication announced up to that point due to the detection of neutrons and the reputation of the lab. On 12 April Pons was acclaimed at an ACS meeting. But Georgia Tech retracted their announcement on 13 April, explaining that their neutron detectors gave false positives when exposed to heat. Another attempt at independent replication, headed by Robert Huggins at Stanford University, which also reported early success with a light water control, became the only scientific support for cold fusion in 26 April US Congress hearings.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.